Isolated hepatic melphalan perfusion of colorectal liver metastases: Outcome and prognostic factors in 154 patients

Annals of Oncology

Volumn 19, Issue 6, 2008, Pages 1127-1134

  Van Iersel, L B J ^a   Gelderblom, H ^a   Vahrmeijer, A L ^a   van Persijn van Meerten, E L ^a   Tijl, F G J ^a   Putter, H ^a   Hartgrink, H H ^a   Kuppen, P J K ^a   Nortier, J W R ^a   Tollenaar, R A E M ^a   van de Velde, C J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; Isolated hepatic perfusion; Liver metastases; Melphalan; Prognostic factors

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MELPHALAN; OXALIPLATIN; RALTITREXED;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATIC ARTERY; HUMAN; LAPAROTOMY; LIVER METASTASIS; LIVER PERFUSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; OVERALL SURVIVAL; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; UNIVARIATE ANALYSIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MELPHALAN; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 44849096794     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn032     Document Type: Article

References (34)

1. Weiss L, Grundmann E, Torhorst J et al. Haematogenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol 1986; 150(3): 195-203.
2. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979; 189(4): 496-502.
3. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19(1): 59-71.
4. Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77(7): 1254-1262.
5. Yamamoto J, Shimada K, Kosuge T et al. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 1999; 86(3): 332-337.
6. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351(4): 337-345.
7. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18(16): 2938-2947.
8. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355(9209): 1041-1047.
9. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342.
10. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343(13): 905-914.
11. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22(2): 229-237.
12. Rothbarth J, Pijl ME, Vahrmeijer AL et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 2003; 90(11): 1391-1397.
13. Alexander HR Jr, Bartlett DL, Libutti SK et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16(4): 1479-1489.
14. Alexander HR Jr, Libutti SK, Pingpank JF et al. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 2005; 12(2): 138-144.
15. Bartlett DL, Libutti SK, Figg WD et al. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001; 129(2): 176-187.
16. Solbiati L, Livraghi T, Goldberg SN et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: Long-term results in 117 patients. Radiology 2001; 221(1): 159-166.
17. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: A prospective study. J Clin Oncol 2005; 23(7): 1358-1364.
18. van Iersel LB, Verlaan MR, Vahrmeijer AL et al. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: A clinical and pharmacologic evaluation. Eur J Surg Oncol 2007; 33(7): 874-881.
19. Marinelli A, de Brauw LM, Beerman H et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 1996; 26(5): 341-350.
20. Runia RD, de Brauw LM, Kothuis BJ et al. Continuous measurement of leakage during isolated liver perfusion with a radiotracer. Int J Rad Appl Instrum B 1987; 14(2): 113-118.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
22. Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224(4): 509-520.
23. Mulier S, Ni Y, Jamart J et al. Local recurrence after hepatic radiofrequency coagulation: Multivariate meta-analysis and review of contributing factors. Ann Surg 2005; 242(2): 158-171.
24. van Duijnhoven FH, Jansen MC, Junggeburt JM et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol 2006; 13(5): 651-658.
25. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230(3): 309-318.
26. Elias D, Sideris L, Pocard M et al. Incidence of unsuspected and treatable metastatic disease associated with operable colorectal liver metastases discovered only at laparotomy (and not treated when performing percutaneous radiofrequency ablation). Ann Surg Oncol 2005; 12(4): 298-302.
27. van Etten B, Brunstein F, van IJken MG et al. Isolated hypoxic hepatic perfusion using percutaneous balloon catheter techniques: A phase I and II study. Ann Surg Oncol 2004; 11(6): 598-605.
28. Pingpank JF, Libutti SK, Chang R et al. Phase I study of hepatic arterial melphatan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005; 23(15): 3465-3474.
29. Selzner M, Hany TF, Wildbrett P et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240(6): 1027-1034.
30. Arulampalam TH, Francis DL, Visvikis D et al. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol 2004; 30(3): 286-291.
31. Truant S, Huglo D, Hebbar M et al. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005; 92(3): 362-369.
32. Yan TD, Nunn DR, Morris DL. Recurrence after complete cryoablation of colorectal liver metastases: Analysis of prognostic features. Am Surg 2006; 72(5): 382-390.
33. Nelson R, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver. Cochrane Database Syst Rev 2006 (4): CD003770.
34. Portier G, Elias D, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24(31): 4976-4982.